



Mangold Insight publishes interview with Biosergen's CEO

Mangold Insight have published an interview with Peder Andersen, CEO of Biosergen. The interview expands upon, among other things, the following questions:

What can you tell us about Biosergens main candidate BSG005?

Can you tell us about the competitors and market opportunities for BSG005?

What will the proceeds from the rights issue be used for?

[Click here to see the full interview.](#)

Shareholder letter available on website

For information on how to subscribe in the Rights Issue and a few summarizing words from CEO Peder Andersen, see the shareholder letter published on www.biosergen.net or <https://emission.mangold.se/>.

Advisers

Mangold Fondkommission AB is the financial adviser to Biosergen in connection with the Rights Issue. Advokatfirman Lindahl KB is the legal adviser to the Company in connection with the Rights Issue.

For further information about Biosergen, please contact:

Dr. Peder M. Andersen, CEO

Telephone: +45 2080 2470

E-mail: peder.andersen@biosergen.net

Certified Adviser

Erik Penser Bank

Telephone: +46 8 463 8000

E-mail: certifiedadviser@penser.se

ABOUT BIOSERGEN

Biosergen is a clinical stage biotechnology company that employs all its organisational and financial resources on the clinical development of BSG005. BSG005 is a potentially disruptive antifungal drug with blockbuster potential based on significant safety and potency advantages over competing antifungals, including Amphotericin B, in more than a decade of laboratory and preclinical studies. The research behind BSG005 and its unique properties has been documented in over 20 peer reviewed scientific papers. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS-, cancer- and transplant patients every year. At equal dose levels BSG005 shows a three-to-fourfold potency advantage against relevant fungal strains compared to current standards of care, while being completely free of the kidney toxicity hampering other drugs in its class. The Company is also developing BSG005 *Nano* where the drug is packed in special nano particles to specifically target the lung, often the first affected organ in an invasive fungal infection. BSG005 *Nano Oral* is an extension of BSG005 *Nano*. An oral formulation would greatly increase the usefulness, particularly as a prophylactic and as home treatment after transplants or cancer treatment to prevent invasive fungal infection. Biosergen has received orphan drug status for BSG005 in the United States.